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Background: Vitiligo is a multi-factorial pigmentary skin disorder. Recently, the importance of emotional and
psychological issues is proposed in incidence, progression, relapse and remission of vitiligo. There are limited
studies conducted in developing countries, which assess life quality of patients with vitiligo. The aim of this study
was the application and evaluation of a disease-specific quality of life index in Iranian patients, for the first time.
Methods: This cross-sectional biphasic study was conducted on 25 patients as a pilot and another 173 patients
as the main study group, in Razi Hospital, Tehran, Iran, 2013–2014. Persian version of Vitiligo Quality of Life index
(VitiQoL) was developed with backward-forward method. Based on the pilot study, the validity and reliability were
assessed. The Vitiligo Area and Score Index (VASI), VitiQoL, and their relationship, demographic and clinical
characteristic of patients were measured.
Results: The Mean and standard deviation of the VitiQoL score was 30.5 ± 14.5 (range 0–60 in Persian version).
There was a significant relationship between VASI score and VitiQoL (p = 0.015, r = 0.187). Confirmatory factor
analysis revealed three important factors within VitiQoL: participation limitation, stigma, and behavior. In subscale
analysis based on behavior factor, female patients had poorer quality of life (p = 0.02). Concomitant psychiatric
problems, e.g. anxiety and depression, were not associated with QOL; however, they were near to being meaningful
(p = 0.06, r = 0.14).
Conclusion: VitiQoL is a valid index in estimating life quality of vitiligo patients and has proper relation to disease
severity. Focusing on patient’s life quality is an important entity in the management of vitiligo patients; relevant
supportive group-based consultations and therapies are also important arms when approaching vitiligo.
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Vitiligo is an acquired, multi-factorial and usually
progressive disorder of melanin production. Vitiligo
equally affects males and females as well as all different
races. Vitiligo has various onset-age, distribution pat-
tern and progression course. Vitiligo is the most preva-
lent cutaneous pigmentary disorder. Its prevalence
reaches 0.5–2 %, worldwide. The mean age of onset* Correspondence: nghandi@tums.ac.ir
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age of 40 [1–4].
The aim of vitiligo treatment is to get better skin
appearance, which requires long time, usually 6–18
months. Response to treatment is about 70–75 % and
how to choose a treatment modality depends on severity,
extent and location of disease [5]. Vitiligo Area Scoring
Index (VASI) is one of the most valid indexes for evalu-
ation of disease extent and severity and also it can be
measured in all situations [6]. Vitiligo European Task
Force (VETF) is the best assessor of treatment efficacy;
however, it needs wood lamp and sometimes taking
photograph is necessary [7].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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sues has been raised. Therefore, vitiligo could be consid-
ered as a psychosomatic disorder, which means physical
and psychological factors concomitantly are involved in
appearance, progression, relapse and remission of vitiligo
[8]. Vitiligo imposes a large burden on patients’ lives,
and many patients suffer from shame and embarrass-
ment, low self-confidence, and social isolation [9–17].
Wrong social beliefs exacerbate the problems of viti-
ligo patients. As in women, vitiligo may end in divorce
and some people believe it is God’s punishment for the
sins [18]. In India, sometimes vitiligo is considered as
white leprosy, which has a significant stigma [10].
Although vitiligo has a remarkable impact on quality
of life (QOL) and brings social stigma, most of the stud-
ies on this aspect of vitiligo are based on general cutane-
ous or non-cutaneous quality of life indexes, such as
Dermatology Life Quality Index (DLQI), Skindex-26,
and SF-36 [9–10, 13–17]. It should be noted that vitiligo
is usually asymptomatic, so its effect on quality of life is
much more related to psychological problems, such as
lack of self-confidence [10, 12], unpleasant body images
[19], unsuccessful social relationships [9], and lower
quality of marital relations [13, 20], than the exclusive
physical issues. It has been shown that patients with
vitiligo are at risk of higher social discrimination and
stigma [10, 14, 17, 19, 21].
A disease specific instrument for estimating quality of
life in Vitiligo has been proposed by Lilly et al. at 2013;
named as Vitiligo Quality of Life (VitiQoL) which em-
phasizes on three principal factors including: stigma,
participation limitation, and behavior [4].
In Iran, there are some studies conducted on vitiligo
quality of life, by the means of general indexes [18, 20,
22–25], all confirm poorer QOL especially in women [20]
and poorer QOL compared with some other countries
[22]. Assessment of quality of life of Iranian patients with
vitiligo with a specific index has not been performed. The
purpose of this study was to assess quality of life among
Iranian vitiligo patients with VitiQoL.
Methods
This study was conducted on 173 patients with vitiligo,
in Razi Hospital, Tehran University of Medical Sciences
(TUMS), Tehran, Iran, from April 2013 to September
2014. VitiQoL was used as the specific index for assess-
ment of quality of life in vitiligo patients. The question-
naire consisted of 15 questions with a seven-point
Likert scale (0-6). The final scores could range from 0
to 90, in which, patients with higher scores showed
poorer quality of life.
Two bilingual physicians translated English version of
VitiQoL questionnaire to Persian, then Persian version was
translated to English by another bilingual person who hadnot read the original questionnaire (back to back transla-
tion). Afterward, the final version was compared with the
original English version. Finally, a dermatologist, a commu-
nity and preventive medicine specialist, and a psychiatrist,
confirmed the Persian questionnaire.
VASI score was used to measure severity of the
disease (Additional file 1) [6]. The scores of specific
areas such as hand, foot, breast, and genitalia, also ex-
posed and non-exposed areas, were calculated. “Disease
progression” and “response to treatment” were assessed
in questionnaire, based on the subjective opinion of pa-
tients regarding disease course in the previous month.
The following two questions were asked respectively:
“Did you experience any change in the severity and
number of lesions within the previous month?” (Disease
progression; improving, no change, slowly progressive,
rapidly progressive); and, “How did your lesions re-
spond to treatment in the previous month?” (Response
to treatment; poor, moderate, appropriate). Previous
psychological or other dermatological diseases were
also asked from the patients.
For the pilot study, 25 patients who were referred to
the phototherapy clinic of Razi Hospital and consented
to participate in the study, were selected. These patients
filled the VitiQoL questionnaire in the first session and
2–3 weeks later. In these two sessions, a dermatologist
(KH) as the main investigator of the study, answered any
questions or comments of the patients. She interviewed
the patients regarding their demographic data and
clinical characteristics, and examined disease extent and
depigmentation degree based on VASI score.
After the pilot study, essential modifications were
made based on the opinion of research team on findings
(e.g. change the structure of complicated sentences to be
more comprehensible or use the words that were more
familiar and making sense of the questions). The re-
search team concluded that the patients could not easily
discriminate among 7 items in Likert; therefore, the
Persian version was finalized as 5-item Likert scale
questions (final scores ranged from 0 to 60) (Additional
file 2). The main structure of the original questionnaire
was not changed and no word was omitted or added.
The final questionnaire was used for the second phase
(the main study).
In order to estimate the mean score of VitiQoL based
on the report by Lilly et al. [4], a sample of 139 patients
was necessary. A single estimation of mean was used for
sample size calculation. As the VitiQoL score could
range from 0 to 90, considering a normal distribution,
which included 6 standard deviations, a standard
deviation of 15 was used for calculation of sample size
(n = 97, if d = 3). To compensate for probable missing,
we added 15 % to this calculated number; and finally
173 patients were enrolled in the study.
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have any other stigmatizing disorders or disabilities such
as leprosy or facial deformities and were not mentally re-
tarded or psychotic, also consented to participate in the
study, were enrolled. Ninety patients were recruited
from the general dermatology clinic and 83 patients
from the phototherapy clinic, by convenience sampling.
It should be mentioned that the patients recruited from
phototherapy clinic were under treatment with narrow
band UVB (NBUVB) and most of the patients of general
clinic were on topical steroids or calcineurine inhibitors.
Data was entered in SPSS Statistics 22.0 and analyzed.
Mean, median and standard deviation were used to de-
scribe quantitative data and Kolmogorov-Smirnov Z was
used to assess normality of continuous variables. In the
case of non-significant P values (p > =0.05), parametric t-
test and analysis of variance (ANOVA) were used for
normally distributed variables. For non-normal variables,
Kruskal-Wallis H and Mann-Whitney U test were used
based on the number of categories of the nominal variables.
Pearson correlation coefficient was used for comparison of
two normally distributed variables, and otherwise Spearman
correlation was performed. McNemar test was used to
assess any statistically significant changes in responses to
dichotomous questions. For assessment of correlation
between quality of life and VASI, Spearman correlation
coefficient was used.
In 10 questionnaires, one or more questions were left
blank, but none of them had more than 3 missing items.
In analysis, we did not exclude any uncompleted filled
questionnaire and the limited missing data, were re-
placed with 3 (mid-score).
In psychometric evaluation of VitiQoL questionnaire,
confirmatory factor analysis was performed based on
principal component analysis and Direct Oblimin (as the
rotation method), eigenvalue > 1 and suppression of
absolute value < 0.4.
Patients enrolled based on their consent and data
were analyzed with respect to their confidentiality. The
ethical committee of Tehran University of Medical
Sciences approved the study. Authors had no conflict
of interests to disclose.
Results
In the pilot study, 13 women and 12 men were enrolled.
The mean age was 31.96 years (SD = 12.21) with the
range of 16–63 years. All of them were recruited from
the phototherapy clinic. Analysis of pilot data showed a
favorable face and content validity. In re-test, the reli-
ability was confirmed by a high Cronbach alfa (0.956),
which showed high internal consistency. The two series
of Persian questionnaires were compared with rho-
Spearman test and correlations were satisfactory. The
Spearman correlation coefficient between the scores inthe first time and in the second was 0.847. Concurrent
validity of the Persian version of VitiQoL was confirmed
by significant correlations between self-reported severity
(question 16 of VitiQol) and VitiQoL scores (r = 0.463
and p < 0.05). Including all patients, Cronbach’s alpha of
VitiQol was 0.914.
Demographic data and clinical characteristics of pa-
tients of the main study are shown in Table 1. Table 2
shows VASI and its relationship with clinical data of
patients. Significant relationship between VASI and
treatment group, duration of disease, education, type of
disease (generalized > localized > segmental) and having
another visible skin disorder in addition to vitiligo were
found (P < 0.05). Skin phototype, gender, age, and con-
current or previous psychiatric problems did not show
any significant relationship with VASI (p>0.05).
VASI (total and area’s specific) and its correlation with
VitiQoL have been demonstrated in Table 3. It should
be noted that in analytic evaluation of VASI and quality
of life, data of three patients with nearly universal vitiligo
from general dermatology clinic were excluded as out-
liers; since these patients had the most severe disease
based on VASI, but their universal depigmentation
caused the least prominent disease presentation, com-
paring to other patients with severe non-homogenous
pigmentary lesions. Finally, the VASI data of 170 patients
were analyzed.
The detail of QOL assessment is shown in Table 4.
The mean VitiQoL score was 30.5 (range: 0–60, SD =
14.5, median = 31). Using principal component analysis
and Direct Oblimin method, three factors from Viti-
QoL were extracted: participation limitation (question
number 2-11, 14), stigma (question number 1, 15), and
behavior (question number 8, 12, 13). Overall, women
had poorer QOL (higher VitiQoL scores) than men.
However, in subscale analysis of these three factors of
VitiQoL, the difference was significant only for behavior
factor (and not for participation limitation and stigma)
(p = 0.02). The QOL (based on behavior factor) was
better in patients recruited from the general clinic
than the patients of phototherapy clinic (p = 0.001).
Patients who had disease duration of 5 years or less,
and patients with 15–20 years disease duration, had
better quality of life, although it was not statistically
significant. Quality of life was better in more educated
patients (p > 0.05). Patients without previous history of
other visible cutaneous disorders and patients with
lighter skin phototype had poorer QOL; but it wasn’t
significant (p > 0.05).
Psychiatric problems were associated with poorer
QOL, although the association was not significant (p =
0.06, r = 0.14). QOL was poorer in patients with more
extensive disease, (generalized < localized < segmental),
and the best QOL was observed in slowly progressive
Table 1 Descriptive demographic data of patients with vitiligo
General clinic (n = 90) Phototherapy clinic (n = 83) Total (n = 173)
n % n % n %
Gender Female 36 40 48 57.8 84 48.6
Male 54 60 35 42.2 89 51.4
Age 16–19 13 14.9 15 18.1 28 16.2
20–29 21 23.0 28 33.7 49 28.3
30–39 34 37.9 22 26.5 56 32.4
> = 40 22 24.1 18 21.7 40 23.1
Disease duration (years) <5 46 52.9 17 20.5 63 36.4
5- < 10 13 14.9 20 24.1 33 19.1
10- < 15 13 13.8 24 28.9 37 21.4
15- < 20 6 6.9 7 8.4 13 7.5
> = 20 12 11.5 15 18.1 27 15.6
Education Illiterate 4 4.4 0 0 4 2.3
Grade 1–11 25 27.8 19 22.9 44 25.4
Grade 12 38 42.2 38 45.8 76 43.9
University education 23 25.6 26 31.3 49 28.3
Skin phototype (Fitzpatrick scale) 1,2 3 3.3 1 1.2 4 2.3
3,4 74 82.3 79 95.2 153 88.4
5,6 13 14.4 3 3.6 16 9.2
Type of disease Generalized 76 84.4 72 86.7 148 85.5
Localized 7 7.8 8 9.6 15 8.7
Segmental 7 7.8 3 3.6 10 5.8
Disease progression Improving 25 27.8 57 68.7 82 47.4
No change 16 17.8 17 20.5 33 19.1
Slowly progressive 33 36.7 7 8.4 40 23.1
Rapidly progressive 16 17.8 2 2.4 18 10.4
Response to treatment Poor 32 35.5 18 21.7 50 28.9
Moderate 25 27.7 28 33.7 53 30.6
Appropriate 28 31.1 37 44.6 65 37.6
No treatmenta 5 5.6 0 0 5 2.9
Previous or current psychiatric disease Yes 7 7.8 10 12 17 9.8
No 83 92.2 73 88 156 90.2
Another visible skin disorder other than vitiligo Yes 3 3.3 6 7.2 9 5.2
No 87 96.7 77 92.8 164 94.8
aPatients who were not on any treatment
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(p > 0.05). The QOLs of two treatment groups were not
significantly different (p > 0.05).
There was a significant relationship between VASI score
and quality of life, in a way that higher VASI scores were
associated with poorer quality of life (p = 0.015 r = 0.187).
Regarding VitiQoL subscales, the correlation with VASI
was statistically significant for behavior factor (p = 0.01,
r = 0.254). There were not any significant associations
between VASI of specific areas (head and neck, genitaliaor exposed areas) and QOL (p > 0.05). There were not any
associations between VASI of breast and quality of
life, although in women it was near to be meaningful
(p = 0.07, r = 0.417); nevertheless, in the behavior fac-
tor subscale analysis, significant correlation was dem-
onstrated (p = 0.03, r = 0.22).
Discussion
With regard to relatively high prevalence of vitiligo in
the world [1, 4], involvement of young people [2, 3] and
Table 2 Vitiligo Area Scoring Index (VASI) and its correlation with demographic characteristic of patients with vitiligo
N Mean of VASI Standard deviation of VASI Median of VASI P value
Total 173 8.62 13.09 3.8
Treatment group General Clinic 93 6.08 8.44 1.87 0.04
Phototherapy Clinic 80 8.70 9.09 6.02
Gender Female 84 9.50 14.63 4.44 0.2
Male 89 7.80 11.43 3.18
Age 16–19 28 6.96 9.36 1.71 0.1
20–29 49 7.71 11.86 4.38
30–39 56 7.56 11.85 3.13
> = 40 40 12.38 17.47 6.7
Disease duration (years) <5 63 3.61 5.56 1.54 <0.001
5- < 10 33 7.96 8.97 3.75
10- < 15 37 11.10 14.78 4.56
15- < 20 13 15.34 10.70 12.87
> = 20 27 14.46 21.87 6.55
Education Illiterate 4 19.39 11.77 17.62 0.009
Grade 1–11 44 10.54 16.01 6.33
Grade 12 76 9.12 13.68 3.22
University education 49 5.24 7.63 2.80
Skin phototype (Fitzpatrick scale) 1,2 4 3.97 11.77 1.64 0.2
3,4 153 8.46 13.32 3.75
5,6 16 11.32 12.17 4.94
Type of disease Generalized 148 9.92 13.73 5.54 <0.001
Localized 15 0.77 1.35 0.30
Segmental 10 0.95 1.28 0.40
Disease progression Improving 82 7.49 8.51 4.90 0.6
No change 33 11.11 21.40 3.42
Slowly progressive 40 10.13 13.82 3.87
Rapidly progressive 18 5.81 7.55 1.84
Response to treatment Poor 50 6.69 7.41 3.31 0.4
Moderate 53 8.06 10.88 5.58
Appropriate 65 10.92 17.59 4.19
No treatmenta 5 3.84 6.58 0.33
Previous or current psychiatric disease Yes 17 7.33 8.99 3.42 0.99
No 156 8.76 13.48 4.25
Another visible skin disorder other than vitiligo Yes 9 2.52 2.76 1.59 0.04
No 164 8.95 13.48 4.25
aPatients who were not on any treatment
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quality of life with a specific scale in countries with
various cultural values could be worthwhile. VitiQoL
is originally a questionnaire in English, which recently
has been suggested for estimation of quality of life in
vitiligo patients. In the present study, a Persian
version of this scoring system was designed and
evaluated.Catucci et al. translated VitiQoL to Brazilian Portuguese
(VitiQoL-PB) and performed cultural adaptation and
validation [26]. in the original VitiQoL, one of the limita-
tions of the study was no assessment of test-retest reliabil-
ity. In Catucci study, 16 subjects (21 % of the sample)
completed the VitiQoL-PB for the second time, con-
firming the high test-retest reliability with an intra-
class correlation co-efficient (ICC) of 0.95 (95 % CI,
Table 3 Vitiligo Area Scoring Index (VASI) of total skin and area specific, and correlation of VASI and VitiQol
Mean of VASI Standard deviation
of VASI
Median of VASI Correlation between VASI
and VitiQol
Total (n = 173) 8.62 13.09 3.8
Excluding outliers (n = 170) 7.36 8.84 3.67 p = 0.015 r = 0.187
(Female = 82, Male = 88)
Head and neck 0.52 1.12 1 p = 0.40
Upper limb 2.17 3.41 0.5
Hand 0.66 0.73 0.3
Lower limb 3.68 4.67 1
Foot 1.6 1.22 0.5
Trunk 2.86 5.48 0.5
Non-exposed area 6.57 8.24 2.83
Exposed-area 0.8 0.85 0.79 p = 0.75
Female 0.61 0.66 0.4
Male 0.97 0.69 0.67
Breast 1.44 0.73 0
Female 0.55 0.4 0.9 p = 0.07 r = 0.417
Male 0.14 0.51 0 p = 0.8
Genitalia 0.14 0.26 0.3 p = 0.54
Female 0.2 0.1 0
Male 0.2 0.13 0.6
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were completed Persian version twice by 14–21 days
interval. The reliability of the Persian version was con-
firmed by Cronbach alfa (0.956), which was similar to
original VitiQoL Cronbach’s alpha (0.935) [4] and Brazilian
Portuguese study (Cronbach alpha = 0.944) [26]. Correla-
tions between self-reported severity and VitiQoL scores
(convergent validity) in Persian version (p < 0.05, r = 0.463)
was near to correlation coefficient of the primary study [4]
(p < 0.05, r = 0.51) and Brazilian Portuguese one [26].
In this study, factor analysis revealed three distinct
factors (participation limitation, stigma, and behavior)
within vitiligo quality of life and that these factors were
internally consistent. Also the original factor structure
proposed by Lilly et al. was retained. The correlation
between disease severity and QOL was comparable to
the results of other studies [24]. Better life quality of pa-
tients in general clinic in our study is reasonable, be-
cause of less severity (usually <15–20 % body surface
area (BSA)), and thus, lower VASI scores.
Poorer QOL in female patients based on behavior factor
was logically predictable, since all over the world, aesthetic
issues are more considerable in woman. They express a
higher level of emotional burden, and the disease has
strong impact on their self-steam. This result was compat-
ible with Dolatshahi et al. study [20] to some extent,
which demonstrated relationship between gender and
QOL, so that more attention to this group is needed.This study showed that younger patients had poorer
quality of life, and 20–29 year-old patients experienced
the worst life quality. It makes sense that cosmetic issues
are more troublesome for the younger people; as they
might have unmet needs of being equally considered,
respected and welcome in occupational, social or emo-
tional relationships. Disease duration less than 5 years
and 15–20 years showed better quality of life, which
might reflect higher hopes for successful treatment in
early course of the disease or getting used to the disease
in the long-term.
It was expected that patients with university educa-
tions might be more aware of the nature of problem and
less worried about any potential consequences, hence
have better quality of life. Nevertheless, this study did
not show a significant association between educational
level and QOL, perhaps due to the preponderance of
other educational categories in comparison with univer-
sity education.
According to the literature, vitiligo is considered as
both cause and result of some psychiatric problems
such as anxiety and depression [8–17]; thus history of
other psychiatric problems could potentially add to
the burden of this disorder. As some vitiligo patients
with psychiatric problems might not be aware of their
own disorder and the disorder could have been un-
diagnosed, the association may be even stronger. This
study did not find any associations between skin
Table 4 VitiQol and descriptive demographic characteristics of patients with vitiligo
Number Mean of VitiQol Standard deviation
of VitiQol
Median of VitiQol P value
Treatment group General Clinic 93 28.80 14.64 28.5 0.107
Phototherapy Clinic 80 32.40 14.30 33
Gender Female 84 31.70 15.20 32.5 0.006
Male 89 29.73 13.85 30
Age 16–19 28 30.82 16.40 27.5 0.026
20–29 49 34.32 12.43 36
30–39 56 29.23 14.25 27.5
> = 40 40 28.65 15.47 28.5
Disease duration (years) <5 63 27.60 14.95 24 0.037
5- < 10 33 34.63 15.57 36
10- < 15 37 31.78 13.51 35
15- < 20 13 28.76 12.65 29
> = 20 27 32.74 13.39 32
Education Illiterate 4 37.00 13.44 38.5 0.667
Grade 1–11 44 32.34 16.05 35
Grade 12 76 30.21 14.23 30
University education 49 29.81 13.68 28
Skin phototype (Fitzpatrick scale) 1,2 4 34.50 17.71 29.5 0.408
3,4 153 31.15 14.16 32
5,6 16 26.43 17.05 22
Type of disease Generalized 148 31.61 14.39 32 0.161
Localized 15 28.20 13.87 27
Segmental 10 24.46 15.01 20
Disease progression Improving 82 31.82 14.38 32 0.296
No change 33 32.42 14.17 34
Slowly progressive 40 26.95 15.68 25
Rapidly progressive 18 31.66 11.98 33
Response to treatment Poor 50 31.16 15.29 30 0.195
Moderate 53 31.83 13.13 33
Appropriate 65 30.72 14.95 30
No treatmenta 5 17.20 10.03 14
Previous or current psychiatric disease Yes 17 36.41 12.84 38 0.066
No 156 29.91 14.58 30
Another visible skin disorder other than vitiligo Yes 9 22.77 11.02 20 0.102
No 164 30.98 14.62 32
aPatients who were not on any treatment
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number of patients with phototype 1 and 2 in Fitzpa-
trick scale classification.
There were not any association between VASI of ex-
posed areas (face, hand, foot) and quality of life. Results
were compatible with the Linthorst [15] and Dolatshahi
[20] studies. However it was in contrast to the study by
Ongenae et al. [27], which showed quality of lifeimproves with camouflage. It should be noted that only
15 % of patients had vitiligo involvement limited to non-
exposed areas. The study showed that patients with
higher educational level and those suffering from an-
other skin disorder other than vitiligo, have lower VASI
score, which could be interpreted as alertness and preco-
cious referral of more educated persons and higher sensi-
tivity to skin appearance among patients with other
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that the mean VASI of patients in phototherapy clinic be
higher than general clinic, since dermatologists usually
suggest phototherapy for patients with involvement of
more than 15–20 % of BSA. Also it was reasonable to find
higher VASI scores in patients with more prolonged dis-
order, due to probable progressive nature of the disease.
Limitations
Sampling was performed in a referral university hos-
pital, which may not be representative of all spectrums
of vitiligo patients in the society. Nevertheless, this cen-
ter (Razi Hospital) is the largest dermatology center of
Iran and this might decrease the chance of sampling
bias. Further multi-centric studies are needed to valid-
ate the results.
Minor psychological problems did not prohibit pa-
tients’ enrolment as that exclusion might have led to the
selection of a sub-sample who were potentially healthier
than normal Iranian population [28]. Moreover, based
on previous studies, these psychological problems are ra-
ther higher in patients with vitiligo [8].
Moreover, non-significance of some associations
might have been due to lack of enough power consid-
ering multiple comparisons. In this study, adjustment
for P values was not considered and p less than 0.05
was considered significant.
In Persian version, the original 7-item Likert score of
VitiQoL was reduced to 5, due to the difficulty of the re-
spondents to differentiate between very close measures
of frequency (such as sometimes and occasionally).
Recommendations
Future multi-centric and community-based studies would
be useful to improve the validity and reliability of Persian
version of VitiQoL. Online filling of the questionnaire can
be applied in future research. Finally, designing a trial to
assess and improve patients’ information regarding the
disease characteristics and a before-after evaluation of
QOL would be a novel idea for future studies. It would be
an honor for the authors of this paper to provide other re-
searchers with Persian version of VitiQoL for further stud-
ies on vitiligo patients’ quality of life and the questionnaire
is available upon their written request.
Conclusion
In this study, the Persian version of a specific index for
estimating life quality of patients with vitiligo was devel-
oped. Except in patients with nearly all body surface area
involved, the quality of life was worse when the disease
was more severe. Life of these patients is obviously af-
fected by presence of depigmented skin lesions, espe-
cially in women, younger adults and those with disease
duration of 5–10 years. Finally, quality of life should beconsidered as one of the important outcome measures
of treatments in vitiligo patients.
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